ライフサイエンスコーパス: CYP

1 CYP family genes differ in expression in whole tissue ho

2 CYP reactions in vivo require the cofactor NADPH as the

3 CYP reactions, therefore, are of high interest to the ph

4 CYP-13A12 promotes oxidation of polyunsaturated fatty ac

5 CYP-mediated stereoselective formation of diOH-PCBs from

6 CYPs critical for xenobiotic metabolism are prone to cat

7 chanism for mitochondrial import of family 1 CYPs but also reveal a direct role for mitochondrial CYP

8 tivation by cells expressing CYP1A1 and 2W1, CYPs known to be expressed in high frequency in some tum

9 be made for the promiscuous 2C9, 2D6 and 3A4 CYP isozymes, as well as CYPs 1A2, 2A6, 2B6, 2C8, 2C19 a

10 r acute heart failure, and cytochrome P-450 (CYP) 2C19 genotyping for the acute coronary syndromes.

11 itis (NASH) affect hepatic cytochrome P-450 (CYP) protein expression and activity, and CYP2E1 may pla

12 Cytochrome P-450 (CYP)-derived epoxyeicosatrienoic acids (EETs) possess po

13 inhibition of ENaC, an effect mediated by a CYP-epoxygenase-dependent pathway.

14 erapy, and reported survival advantage for a CYP (17,20) lyase inhibitor in castration-resistant pros

15 rst to establish a biological activity for a CYP-produced metabolite of DGLA.

16 mized model of the R108H mutant maintained a CYP fold, despite substantial movement of several loop r

17 line of zebrafish had been generated using a CYP-green fluorescence protein (CYP-GFP) construct, driv

18 ed secondary metabolites from chicory affect CYP expression and thereby might affect detoxification i

19 d no significant inhibition activity against CYP-3A4.

20 All CYP substrates and their metabolites were analyzed using

21 , encoding the single electron donor for all CYPs.

22 71 clan now represents more than half of all CYPs in higher plants.

23 Using transgenic mice with altered CYP lipid biosynthetic pathways in a mouse model of lase

24 this underrepresentation of 1,2,3-TRZs among CYP inhibitors, thermodynamic and density functional the

25 nificantly as plants matured, as did ADS and CYP transcripts.

26 t of the substrate classes of ADH, ALDH, and CYP.

27 ed by a putative EET receptor antagonist and CYP epoxygenase inhibitor, directly implicating CYP epox

28 Generation and analysis of key BACE1 and CYP 2D6 crystal structures identified strategies to obvi

29 cyte stability, rat free brain exposure, and CYP inhibition and induction liabilities.

30 nical candidate ispinesib, moderate hERG and CYP inhibition.

31 s, aqueous solubility, cell permeability and CYP inhibition, deeming it a suitable compound for in vi

32 equired metabotropic glutamate receptors and CYP omega-hydroxylase, the enzyme regulating 20-hydroxye

33 inhibition potency, kinase selectivity, and CYP inhibition and possesses pharmacokinetics suitable f

34 Cigarette smoking and CYP genotype did not have any significant influence on r

35 oach to improve the microsomal stability and CYP inhibition profile of lead compounds 1a and 1b led t

36 es in terms of its microsomal stability, and CYP and hERG inhibition, along with an excellent brain p

37 observation of the unique pattern of TS and CYP assembly in eudicots and monocots.

38 ch of sequenced plant genomes for all TS and CYP genes reveals that distinct TS/CYP gene pairs are fo

39 by mixing and matching of individual TS and CYP genes through dynamic genome rearrangements.

40 ive pathway genes, transcription factors and CYPs related to camptothecin (CPT) biosynthesis.

41 emonstrate new functional pairing of TSs and CYPs within previously uncharacterized clusters.

42 us 2C9, 2D6 and 3A4 CYP isozymes, as well as CYPs 1A2, 2A6, 2B6, 2C8, 2C19 and 2E1.

43 hylamine series to afford potent, dual BACE1/CYP 3A4 inhibitors which demonstrate improved penetratio

44 in the physiological significance of bimodal CYP targeting to the endoplasmic reticulum and mitochond

45 interference studies demonstrated that both CYPs are promiscuous.

46 s and rodents in neocorticogenesis and brain CYP metabolism, translation of the research findings fro

47 ll of the relevant lipid species produced by CYP pathways.

48 ization of three novel compounds produced by CYP-mediated oxidation.

49 ive metabolism of chiral PCBs and OH-PCBs by CYPs is a major mechanism for atropisomer composition ch

50 rse spectrum of lipid nutrients regulated by CYPs, but also clearly indicate that the balance of thes

51 Vitreous also contained CYP-derived epoxyeicosatrienoic acids; their levels were

52 ion strategies that have been used to create CYP biosensors, with particular emphasis on mammalian dr

53 d gels remain robust strategies for creating CYP biosensors; however, the incorporation of novel mate

54 ll interfering RNA knockdown of cyclophilin (CYP)A, CYPC, or CYPD in HepG2215 cells, or CYPA knockdow

55 ecreased in the bladder of cyclophosphamide (CYP)-treated mice, a commonly used model of bladder over

56 paration from untreated or cyclophosphamide (CYP) treated rats.

57 localized disease received cyclophosphamide (CYP) as part of the induction regimen.

58 We reported here that cyclophosphamide (CYP)-induced cystitis significantly increased the produc

59 sium channel protein inhibition, and CYP3A4 (CYP = cytochrome P450) inhibition are influenced by the

60 ase (ADS) and the cytochrome P450, CYP71AV1 (CYP), were more highly correlated with AN's immediate pr

61 g properties of MIP-QDs toward cypermethrin (CYP) are due to strong interactions between these molecu

62 productive substrate binding among different CYP isoforms.

63 ed EETs or compared the effects of different CYP epoxygenase isoforms in the ischemic heart.

64 The quest to create electroactive CYPs has led to many different immobilization strategies

65 In this study we found that C. elegans CYP-33E2 activity produces a range of epoxy and hydroxy

66 Although endothelial CYP-derived EETs are potent vasodilators, their contribu

67 data demonstrate that increased endothelial CYP epoxygenase expression attenuates afferent arteriola

68 We conclude that endothelial CYP epoxygenase function contributes to the regulation o

69 Screening with selective enzymatic CYP inhibitors identified CYP2A6 as the major isoform in

70 le in the active site of the target enzymes, CYPs 51, from several pathogenic species.

71 enase (LO)- and cytochrome P450 epoxygenase (CYP)-derived eicosanoids.

72 0 IC(50) of 10 nM) was further evaluated for CYP selectivity using a panel of CYP enzymes, mutagenici

73 multicenter TRIUMPH study were genotyped for CYP polymorphisms.

74 mpounds in drug development are screened for CYP activity.

75 Both loss-of-function and gain-of-function CYP polymorphisms affecting clopidogrel metabolism are a

76 Common functional CYP genetic variants do not affect active drug metabolit

77 proteases, which, in combination with a good CYP inhibition profile, suggested low off-target toxicit

78 nase 3 titers than patients who did not have CYP.

79 bition (IC50 > 50 muM) of a panel of hepatic CYP enzymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, a

80 rd ERalpha and ERbeta, inhibition of hepatic CYP enzymes, metabolic stability, and inhibition of marm

81 = 422), CYP17, CYP19, and a panel of hepatic CYP enzymes.

82 f chicory root, on the expression of hepatic CYP mRNA (1A2, 2A19, 2C33, 2D25, 2E1 and 3A29), using pr

83 pounds with low metabolic stability and high CYP inhibition, whereas the protective effect of bromine

84 bility, and most are selective against human CYPs 1A2, 2D6, and 3A4 (<50% inhibition at 1 muM).

85 Recombinant human CYPs (CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2

86 liver microsomes (HLM) and recombinant human CYPs, and to identify the CYP(s) that are active in the

87 The immobilized CYP can then act as a biosensor for the detection of CYP

88 However, immobilizing CYPs on an electrode can eliminate the need for NADPH an

89 epoxygenase inhibitor, directly implicating CYP epoxygenase-derived EETs with the observed anti-infl

90 thiazole, along with analogues with improved CYP inhibition profile.

91 In CYP treated preparations SNAP also decreased by 33-55% B

92 Despite great interest in CYP enzymology, two in vitro aspects of CYP3A4 catalysis

93 the operation of the peroxo intermediate in CYP-catalyzed deformylation.

94 the nitrogen can change regioselectivity in CYP metabolism.

95 m 79 +/- 15 spikes/s to 44 +/- 8 spikes/s in CYP pretreated but not untreated preparations.

96 associations between functional variants in CYP genes, plasma concentrations of active drug metaboli

97 The observed SNP-directed variation in CYP functionality indicated that vitamin D homeostasis i

98 The changes in CYPs account for the gender differences in porphyria and

99 and porphyria associate with differences in CYPs, oxidative injury, and selective keratin induction.

100 However, the effect of increased CYP-mediated EET biosynthesis and decreased soluble epox

101 ct of AA and 11,12-EET on ENaC by increasing CYP epoxygenase activity and decreasing sEH activity, re

102 rease clopidogrel responsiveness by inducing CYP activity.

103 macodynamic studies to competitively inhibit CYP activation of clopidogrel, reducing clopidogrel resp

104 leaves with AN or artemisinic acid inhibited CYP transcription; artemisinic acid also inhibited ADS t

105 7-click] highlights the risk of interpreting CYP-ligand complex structure on the basis of optical spe

106 the toxicity and drug interactions involving CYP enzymes.

107 iated with several cytochrome P450 isoforms (CYPs): 7-ethoxyresorufin-O-deethylase (EROD), benzyloxy-

108 in the neutral OHCs, we suggest that a lower CYP-mediated metabolic activity can partially explain th

109 n and its BTPs, in vivo assays for measuring CYP activities, and G. pulex video-tracking suggested th

110 tivity of inhibitors against human metabolic CYP enzymes is presented.

111 issues in the context of lipid-metabolizing CYP enzymes, focusing particularly on the CYP450 family

112 3A4) is the dominant xenobiotic metabolizing CYP.

113 ular emphasis on mammalian drug-metabolizing CYPs and characterization of CYP electrodes.

114 While the cytochrome P450 monooxygenases (CYP) from the CYP79 family forming aldoximes as biosynth

115 enzyme class cytochrome P450 monooxygenases (CYPs), thereby influencing the detoxification of co-occu

116 ification of cytochrome P450 monooxygenases (CYPs/P450s), great progress has been made in understandi

117 ults highlight the incorporation of multiple CYPs into diterpenoid metabolic engineering, and a conti

118 The function of nonmammalian CYPs are largely unknown and tools for characterization

119 to date have investigated the association of CYP variants with outcomes in black patients.

120 ug-metabolizing CYPs and characterization of CYP electrodes.

121 then act as a biosensor for the detection of CYP activity with potential substrates, albeit only if t

122 It was devoid of CYP inhibition and was approximately 4000-fold selective

123 The effect of CYP polymorphisms on cardiovascular events among clopido

124 The effect of CYP polymorphisms on the clinical outcomes in patients t

125 n the sex-based differences in expression of CYP family members and X-ist, which potentially leads to

126 n presented non-time-dependent inhibition of CYP activities in both human and rat liver.

127 c modeling, we showed that the inhibition of CYP-catalyzed biotransformation reactions indeed played

128 tigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a va

129 od bioavailability, high solubility, lack of CYP inhibition and low hepatotoxicity.

130 rom fish samples spiked with three levels of CYP.

131 ing foods remain to be evaluated in light of CYP pharmacogenetics.

132 derlying mechanism of cyt b(5) modulation of CYP catalysis.

133 It is found that the F429H mutant of CYP 2B4 undergoes homolytic instead of heterolytic O-OH

134 aluated for CYP selectivity using a panel of CYP enzymes, mutagenicity (Ames screen), and hepatic sta

135 successfully employed to detect residual of CYP in fish samples.

136 al. evaluate in a systematic way the role of CYP epoxygenases and the metabolites they generate in ca

137 The role of CYP was assessed in human liver microsomes (HLM) and tyr

138 bolic engineering, and a continuing trend of CYP promiscuity generating complex networks in terpenoid

139 relapse, which may be related to less use of CYP in the induction regimen.

140 er voiding and restores the voided volume of CYP-treated mice.

141 However, functional characterization of CYPs has been challenging because of the expansive famil

142 In this study, we examined the effects of CYPs on the ligand responses of ORs in heterologous cell

143 t of the activity and coupling efficiency of CYPs using capillary electrophoresis with UV detection.

144 ling is an integral part of the induction of CYPs by ozone.

145 noamine oxidases shows minimal inhibition of CYPs and hERG and inhibits proliferation and survival in

146 different poplar parts via the inhibition of CYPs.

147 evidence that nitrogenous type II ligands of CYPs can be efficiently metabolized.

148 associated with translational repression of CYPs.

149 o affect the expression of a distinct set of CYPs, including 1A1, 1A2, 2B6, 2C8, 3A4, and 7A1, but no

150 A subgroup of CYPs metabolize omega3-arachidonic and linoleic acids an

151 The huge superfamily of CYPs found in angiosperms is built on the successful evo

152 quently, any laboratory or industrial use of CYPs is limited by the need to supply NADPH and CPR.

153 d-type (WT), confirming strong reduction of (CYP-mediated) BS synthesis.

154 g interactions (DDI) were predicted based on CYP 2D6 affinities.

155 enum DS50662, a new cytochrome P450 (P450 or CYP) from Amycolatopsis orientalis (CYP105AS1) was isola

156 YP2C8, making CYP2C8 distinct from the other CYP isoforms.

157 urbitacin core skeleton as well as two other CYPs responsible for the key structural variations among

158 enabled us to unveil a novel multi-oxidation CYP for the tailoring of the cucurbitacin core skeleton

159 everal biosynthetic and xenobiotic-oxidizing CYP enzymes of biomedical importance.

160 we found that the cytochrome P450 oxygenase CYP-13A12 acts in response to the EGL-9-HIF-1 pathway to

161 graft mice model, combination of P-DTX and P-CYP showed the most effective and persistent tumor growt

162 C-3 or RC-92a/hTERT prostate cancer cells, P-CYP preferentially kills and impairs the function of CD1

163 tes: HPMA copolymer-cyclopamine conjugate (P-CYP) preferentially toxic to cancer stem/progenitor cell

164 133+ cancer cells following combination or P-CYP treatments, indicating selective killing of cancer c

165 Cytochrome P450 (CYP) 1A1 is an extrahepatic monooxygenase involved in th

166 mediated utilization of the cytochrome P450 (CYP) 1A1 to obtain the selective release of potent antic

167 Cytochrome P450 (CYP) 1B1 is implicated in vascular smooth muscle cell mi

168 metabolism by talarozole, a cytochrome P450 (CYP) 26 specific inhibitor, increased the effects ofatRA

169 riguing deactivation of the cytochrome P450 (CYP) 2B4 enzyme induced by mutation of a single residue,

170 evirapine is metabolized by cytochrome P450 (CYP) 2B6 and CYP3A4.

171 n mediated predominantly by cytochrome P450 (CYP) 2B6.

172 Human cytochrome P450 (CYP) 2C enzymes metabolize approximately 30% of clinical

173 ent confirmed inhibition of cytochrome P450 (CYP) 2C19 and CYP3A4 by meropenem, suggesting that durin

174 The degree to which cytochrome P450 (CYP) 2C19 genotype influences the effectiveness of clopi

175 coronary artery disease for cytochrome P450 (CYP) 2C19 genotypes and enrolled 103 patients who lacked

176 he loss-of-function hepatic cytochrome P450 (CYP) 2C19*2 allele has been associated with reduced clop

177 elective inhibitor of human cytochrome P450 (CYP) 2C9 isozyme, was identified as a novel and leading

178 /mutagenic intermediates by cytochrome p450 (CYP) 2D6 and CYP2E1 enzymes.

179 Human microsomal cytochrome P450 (CYP) 2E1 is widely known for its ability to oxidize >70

180 Cytochrome P450 (CYP) 3A accounts for nearly 30% of the total CYP enzymes

181 d that dronedarone inhibits cytochrome P450 (CYP) 3A4 and 3A5 in a time-dependent manner.

182 ts tacrolimus metabolism by cytochrome P450 (CYP) 3A4 and could lead to tacrolimus overexposure in pa

183 Cytochrome P450 (CYP) 4A and 4F enzymes metabolize arachidonic acid to 20

184 n to uncover the effects of cytochrome P450 (CYP) 4A in TAMs on lung pre-metastatic niche formation a

185 ene oxidase (KO), as such a cytochrome P450 (CYP) 701 family member is required for gibberellin (GA)

186 f indole-3-acetic acid, and Cytochrome P450 (CYP) 71B6 were found to be transcriptionally coexpressed

187 intestinal inflammation and cytochrome P450 (CYP) activities.

188 The mechanisms of cytochrome P450 (CYP) catalyzed C-C bond cleavage have been strongly deba

189 rdinate to the heme-iron of cytochrome P450 (CYP) enzymes are assumed to increase metabolic stability

190 Mtb H37Rv strain encodes 20 cytochrome P450 (CYP) enzymes, many of which are implicated in Mtb surviv

191 ng monooxygenase (FMO), and cytochrome P450 (CYP) enzymes.

192 etabolites involves several cytochrome P450 (CYP) enzymes.

193 sEH limits tissue levels of cytochrome P450 (CYP) epoxides derived from omega-6 and omega-3 polyunsat

194 tes the renal expression of cytochrome P450 (CYP) epoxygenase 2C23, which metabolizes arachidonic aci

195 between endocannabinoid and cytochrome P450 (CYP) epoxygenase metabolic pathways.

196 Cytochrome P450 (CYP) epoxygenases CYP2C8 and CYP2J2 generate epoxyeicosa

197 Cytochrome P450 (CYP) epoxygenases generate bioactive lipid epoxides whic

198 ed from arachidonic acid by cytochrome P450 (CYP) epoxygenases have beneficial effects in certain car

199 yl side chain by enzymes of cytochrome P450 (CYP) families 125 and 142.

200 Cytochrome P450 (CYP) family members are known to be present in the olfac

201 ate synthetase1 and several cytochrome P450 (CYP) genes in this culture system.

202 , the expression of several cytochrome P450 (CYP) genes were also modified in both fungi by MP4, whic

203 TRZ) is unrepresented among cytochrome P450 (CYP) inhibitors.

204 nsport in humans, including cytochrome P450 (CYP) isoform 7A1 (CYP7A1), CYP27A1, CYP8B1, uridine 5'-d

205 a prodrug, requires hepatic cytochrome P450 (CYP) metabolic activation to produce the active metaboli

206 ubstrates and inhibitors of cytochrome P450 (CYP) metabolism enzymes identified from published in vit

207 osome 4, which contains two cytochrome P450 (CYP) mono-oxygenases, CYP99A2 and CYP99A3, with undefine

208 atty acids derived from the cytochrome P450 (CYP) monooxygenase pathway serve as vital second messeng

209 h hepatic disruption of the cytochrome p450 (CYP) oxidoreductase gene, encoding the single electron d

210 attributes and metabolizing cytochrome P450 (CYP) polymorphisms on clinical outcome.

211 rt related to the effect of cytochrome P450 (CYP) polymorphisms on its metabolism.

212 hesis that enzymes from the cytochrome P450 (CYP) superfamily can participate in the catalysis of non

213 st all known members of the cytochrome P450 (CYP) superfamily conserve a key cysteine residue that co

214 A by certain members of the cytochrome P450 (CYP) superfamily helps to maintain tissue RA concentrati

215 Cytochrome P450 (CYP)-dependent eicosanoids regulate vascular function, i

216 e investigated the roles of cytochrome P450 (CYP)-derived epoxy-oxylipins in a well-characterized mod

217 Renal cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) regulate s

218 Cooling decreases cytochrome P450 (CYP)-mediated drug metabolism, and limited clinical data

219 t predicts isozyme-specific cytochrome P450 (CYP)-mediated sites of metabolism (SOMs) on drug-like mo

220 The cytochrome P450 (CYP)-specific bioactivity of the liver microsomal film o

221 se (BIS), is catalyzed by a cytochrome P450 (CYP).

222 Cytochrome P450 (CYP)1A enzymes are protective against hyperoxic lung inj

223 (TCDD) on the expression of cytochrome P450 (CYP)1A1 and cytokines in various tissues of mice.

224 s suppressed BaP+BC-induced cytochrome P450 (CYP)1A1/1A2 expression by 10-50%.

225 Mutations in the cytochrome p450 (CYP)21A2 gene, which encodes the enzyme steroid 21-hydro

226 Cytochrome P450 (CYP)2C9 and CYP2C19 are important human enzymes that met

227 sent in 8 sera; 11 had anti-cytochrome P450 (CYP)2E1 Abs, 14 had Abs against CYP2E1 modified by INH,

228 thylation for X-ist and for cytochrome P450 (CYP; family members 1a1, 2e1m, and 7b1.

229 valuation of the microsomal cytochrome-P450 (CYP) enzymes revealed significant gender differences in

230 In contrast, silencing of cytochromes P450 (CYP) 1A, main AHR-induced genes, did not alter TCDD supp

231 Cytochromes P450 (CYP) from the 2A subfamily are known for their roles in

232 Cytochrome P450 (CYPs) is significant in degradation of endogenous substr

233 the reactions catalyzed by cytochromes P450 (CYPs or P450s), which are responsible for the metabolism

234 to various membrane-bound cytochromes P450 (CYPs) and their electron transferring protein partners,

235 Cytochromes P450 (CYPs) are potential enzymes responsible for hydroxylatio

236 Cytochromes P450 (CYPs) play a key role in generating the structural diver

237 e scaffold diversity), and cytochromes P450 (CYPs), which modify and further diversify these scaffold

238 id synthetic enzymes (e.g., cytochrome P450 [CYP]7A1/Cyp7a1 and CYP8B1/Cyp8b1).

239 Cytochrome P450 (P450, CYP) 17A1 plays a critical role in steroid metabolism, c

240 Cytochrome P450 (P450, CYP) 21A2 is the major steroid 21-hydroxylase, convertin

241 pharmacokinetic relevance (cytochrome P450; CYP).

242 up-regulated genes include cytochrome P450s (CYP) CYP6P9a, CYP6P9b and CYP6M7.

243 Cytochrome P450s (CYPs) are a large family of heme-containing monooxygenas

244 Cytochrome P450s (CYPs) are functionally diverse monooxygenases responsibl

245 tudies have indicated that cytochrome P450s (CYPs) are involved in the metabolism of polybrominated d

246 osine hydroxylase (TH) and cytochrome P450s (CYPs) catalyzed this process.

247 port plant metabolism, the cytochrome P450s (CYPs) constitute an excellent reporter of metabolism arc

248 Characterization of the cytochrome P450s (CYPs) identified from these loci enabled us to unveil a

249 m of SlMIXTA-like included cytochrome P450s (CYPs) of the CYP77A and CYP86A subfamilies, LONG-CHAIN A

250 The cytochrome P450s (CYPs) represent a highly divergent class of enzymes invo

251 sm of clopidogrel requires cytochrome P450s (CYPs), including CYP2C19.

252 he creation of highly sensitive and portable CYP biosensors.

253 ependent nonlinear PK and is likely a potent CYP 3A inhibitor.

254 CYP2B6 was the predominant CYP capable of forming six OH-BDEs, including 3-OH-BDE-4

255 ated using a CYP-green fluorescence protein (CYP-GFP) construct, driven by CYP1A1 promoter.

256 Patients who received CYP during induction had significantly (P = 0.027) lower

257 in enhanced metabolic stability and reduced CYP inhibition.

258 e knock-down of this pair of closely related CYPs reduced momilactone accumulation.

259 netic studies have demonstrated that several CYP proteins are capable of metabolizing at-RA; however,

260 ion that is highly dependent on the specific CYP isoform and substrate interaction.

261 all induced increased expression of specific CYPs, while esculin showed no effect.

262 ance of selectivity over other steroidogenic CYP enzymes, in particular 11beta-hydroxylase (CYP11B1),

263 to OH-PCB3s in whole poplars because suicide CYP inhibitors ABT and ODYA both led to sharp decreases

264 All results pointed to the conclusion that CYP enzymes were the agents which metabolized PCB3 to OH

265 We show that CYP enzymes can metabolize multiple sterols in vitro, es

266 These results suggest that CYP lipid signaling molecules and their regulators are p

267 tion of CYP3A degradation has indicated that CYPs 3A incur ubiquitin-dependent proteasomal degradatio

268 The CYP complement (CYPomes) of rice and the model grass wee

269 The CYP subfamily 2J polypeptide 2 (CYP2J2) was upregulated

270 amptic features that were ameliorated by the CYP epoxygenase inhibitor N-(methylsulfonyl)-2-(2-propyn

271 ydroxytestosterone and its inhibition by the CYP-specific ketoconazole inhibitor.

272 recombinant human CYPs, and to identify the CYP(s) that are active in the oxidative metabolism of BD

273 se data demonstrate that potentiation of the CYP epoxygenase pathway by either increased endothelial

274 death of photoreceptors and suggest that the CYP monooxygenase system is a risk factor for retinal ph

275 We discovered that the CYP-derived lipid metabolites epoxydocosapentaenoic acid

276 Among the CYPs tested, co-expression of CYP1a2 significantly affec

277 ive miRNA binding sites on the 3'UTRs of the CYPs were identified in-silico.

278 tigate their synergistic potential and their CYP inhibition strength in the aquatic invertebrate Gamm

279 e underlying evolutionary expansion of these CYP appears to have occurred after assembly of the ances

280 t, when we promoted the degradation of these CYP-derived metabolites by transgenic overexpression of

281 ow starting to discern the patterns of these CYP-PUFA products in health and disease.

282 These CYPs had similar transcription profiles to that of the k

283 therapeutic index drugs metabolized by these CYPs require close monitoring.

284 reover, we demonstrated the utility of these CYPs by engineering yeast for heterologous production of

285 zation of the WT CYP105AS1 reveals that this CYP is an efficient compactin hydroxylase, but that pred

286 derstanding of the azole binding not only to CYPs 51 from the pathogenic species but also to differen

287 CYP) 3A accounts for nearly 30% of the total CYP enzymes in the human liver and participates in the m

288 d be expected by chance, and that certain TS/CYP pairings predominate, providing signals for key even

289 ll TS and CYP genes reveals that distinct TS/CYP gene pairs are found together far more commonly than

290 s; in the former, microsyntenic blocks of TS/CYP gene pairs duplicate and provide templates for the e

291 We recover TS/CYP gene pairs for previously characterized terpene meta

292 Therefore, two CYP suicide inhibitors, 1-aminobenzotriazole (ABT) and 1

293 Here we present the characterization of two CYPs, CYP76AH3 and CYP76AK1, which act sequentially to f

294 Additionally, 1 possesses a unique CYP profile and was found to be a regioselective inhibit

295 Rifampin (RIF) upregulates CYP 450 isoenzymes, potentially lowering efavirenz (EFV)

296 all signs of T. cruzi infection in mice when CYP metabolism was inhibited, with sterile cure achieved

297 that the generation of BACE1 inhibitors with CYP 3A4 inhibitory activities in this scaffold affords c

298 hermore, they display fewer liabilities with CYP-metabolizing enzymes and hERG compared with ispinesi

299 his method showed a linear relationship with CYP concentration over the range of 0.05-60.0 mg/kg with

300 excitability and urothelial ATP release with CYP-induced cystitis is decreased with TGF-beta inhibiti